Breaking News

Pharmatek Launches API-in-capsule Mfg. Program

May 1, 2014

Filling drug directly into capsules aims to cut time to clinic

Pharmatek has launched its new API-in-capsule manufacturing program, designed to lower development costs, shorten timelines and increase capsule throughput, according to the company.
   
As part of the program, the company recently expanded it facility with two cGMP manufacturing suites designed specifically for API-in-capsule productions, and features humidity control and inert gas systems designed to contribute to a more robust manufacturing process.
 
The company has also implemented operational systems, including dedicated project teams, streamlined batch records, extended shift operations, redundant equipment and change parts, and on-demand inventory management.  
 
“We have seen more and more clients push the envelope on how far they will take API-in-capsule in development. No longer is the technology seen as a Phase I-only solution,” said Pharmatek president Tim Scott. “And because micro-dose systems are not keeping up with the scale required for larger batches, we looked for ways to improve efficiencies, both in terms of reducing costs and speeding up processes.”
 
"By implementing the new API-in-capsule program, Pharmatek has increased capsule throughput and reduced production times by as much as 50%,” said Pharmatek director of manufacturing, Kevin Rosenthal. “Additionally, the program has enabled Pharmatek to lower the overall cost of API-in-capsule productions and pass substantial savings on to our clients.”
 
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks